Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)

European Journal of Cancer

Volumn 35, Issue 9, 1999, Pages 1338-1342

  Maindrault Goebel, F ^a   Louvet, C ^a   Andre T ^b   Carola, E ^c   Lotz, J P ^b   Molitor, J L ^a   Garcia, M L ^a   Gilles Amar, V ^a   Izrael, V ^b   Krulik, M ^a   De Gramont, A ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b HÔPITAL TENON   (France)

^c Hopital de Senlis   (France)

Author keywords

5 Fluorouracil; Leucovorin; Metastatic colorectal cancer; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS;

EID: 0033198085     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00149-5     Document Type: Article

References (17)

1. Raymond E., Faivre S., Woynarowski J.M., Chaney S.G. Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol. 25(Suppl. 5):1998;4-12.
2. Machover D., Diaz-Rubio E., de Gramont A.et al. Two consecutive phase II studies of oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol. 7:1996;95-98.
3. Lévi F., Misset J.L., Brienza S.et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. Cancer. 69:1992;893-900.
4. de Gramont A., Louvet C., André T.et al. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Eur. J. Cancer. 34:1998;619-626.
5. de Gramont A., Gastiaburu J., Tournigand C.et al. Oxaliplatin with high-dose folinic acid and 5-fluorouracil 48 h infusion in pretreated metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 13:1994;220.
6. de Gramont A., Vignoud J., Tournigand C.et al. Oxaliplatin with high leucovorin and 5-fluorouracil 48-h continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer. 33:1997;214-219.
7. André T., Louvet C., Raymond E.et al. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann. Oncol. 9:1998;1-3.
8. André T., Bensmaine M.A., Louvet C.et al. Addition of oxaliplatin to the same leucovorin and 5-fluorouracil bimonthly regimens after progression in patients with metastatic colorectal cancer. ECCO9. Eur. J. Cancer. 33(Suppl. 8):1997;S165.
9. Tournigand C., de Gramont A., Louvet C.et al. A simplified bimonthly regimen with leucovorin and 5 FU for metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 17:1998;274.
10. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
11. MacDonald J., Haller D., Mayer R. Grading of toxicity. MacDonald J., Haller D., Mayer R. Manual of Oncologic Therapeutics. 1995;519-523 Philadelphia, Lippincott.
12. Mori A., Bertoglio S., Guglielmi A.et al. Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemother. Pharmacol. 33:1993;179-180.
13. de Gramont A., Louvet C., Bennamoun M.et al. Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer. J. Infus. Chemother. 2:1996;97-101.
14. Rougier P., Van Custem E., Bajetta E.et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 352:1998;1407-1412.
15. Cunningham D., Pyrhönen S., James R.D.et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 352:1998;1413-1418.
16. Levi .F, Zidani R., Misset J.L. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 350:1997;681-686.
17. de Gramont A., Figer A., Seymour M.et al. A randomized trial of leucovorin and 5-fluorouracil with or without oxaliplatin in advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 17:1998;257a.